WO2007030928A2 - Method for the diagnosis of colorectal cancer and ovarian cancer by the measurement of vitamin e-related metabolites - Google Patents
Method for the diagnosis of colorectal cancer and ovarian cancer by the measurement of vitamin e-related metabolites Download PDFInfo
- Publication number
- WO2007030928A2 WO2007030928A2 PCT/CA2006/001502 CA2006001502W WO2007030928A2 WO 2007030928 A2 WO2007030928 A2 WO 2007030928A2 CA 2006001502 W CA2006001502 W CA 2006001502W WO 2007030928 A2 WO2007030928 A2 WO 2007030928A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- metabolites
- crc
- derivatives
- vitamin
- group
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57419—Specifically defined cancers of colon
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57449—Specifically defined cancers of ovaries
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/82—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving vitamins or their receptors
Definitions
- the present invention relates to the diagnosis, of colorectal and ovarian cancer (CRC and OC, respectively).
- CRC and OC colorectal and ovarian cancer
- the present invention describes the relationship between endogenous small molecules and CRC or OC.
- the present invention relates to the diagnosis of CRC and OC through the measurement of vitamin E-related metabolites.
- the present invention also relates to diagnostic markers identified in said method.
- Colorectal Cancer is the third most common malignancy in the world, and represents approximately ten percent of the world's total cancer incidence [I]. Due to the aging world-wide population, CRC represents a serious public health problem requiring new actions that will minimize the impact of this disease. The chance of surviving CRC is closely related to the stage of the disease at diagnosis (as shown in Table 1; http://www.alternative-cancer- treatments.com/colon-cancer-prognosis.htm); the earlier the diagnosis, the greater the likelihood of survival. For example, there is less than a 5% chance of 5-year survival when diagnosed late in the disease timeframe (Dukes' stage D), while there is greater than 90% chance of 5-year survival when diagnosed early (Dukes' stage A). Therefore, CRC patients would greatly benefit from early detection because of the effectiveness of surgical treatment early on.
- the most common current screening tests for CRC are: 1) the fecal occult blood test (FOBT), which is based on the assumption that cancers will bleed, and can therefore be detected in the stool using chemical or immunological assays; and 2) invasive methods that identify gross abnormalities.
- the FOBT is the most widespread test used for CRC, and involves a crude test for the peroxidase-like activity of heme in hemoglobin.
- the sensitivity of the test is only approximately 50%, with a 20% sensitivity for adenomas, due to the fact that not all adenomas and CRCs bleed [2].
- Methods for identifying gross abnormalities can include flexible sigmoidoscopy and colonoscopy, as well as double-contrast barium enema and virtual colonoscopy.
- Colonoscopy is the next test for patients with a positive FOBT, and, with an 80% false positive rate, imposes unnecessary hazards and risks to a large number of individuals.
- Colonoscopy is usually the preferred method for screening average and increased-risk individuals over the age of 50 who have a history of CRC or prior adenomatous polyps, or other predisposing diseases such as inflammatory bowel disease.
- colonoscopy is still the standard test for the presence or absence of polyps and CRC, it can miss 15% of lesions >1 cm in diameter [5].
- Complications with colonoscopy can include perforation, hemorrhage, respiratory depression, arrhythmias, and infection [6].
- Approximately one in 1,000 patients suffer perforations and three in 1,000 experience hemorrhaging. Between one and three deaths out of 10,000 tests occur as a result of the procedure [3].
- Other disadvantages such as the lack of trained personnel, patient discomfort, and high cost will likely prevent the colonoscopy from becoming a routine CRC screening method for the general population (see Table 2).
- CTC Computerized Tomography Colonography
- virtual colonoscopy is a recent non-invasive technique for imaging the colon, with reports varying dramatically on the performance characteristics of the assay (ranging between 39% and 94% specificity), due primarily to technological differences in the patient preparation and the hardware and software used for the analysis.
- Other limitations of CTC include high false-positive readings, inability to detect flat adenomas, no capacity to remove polyps, repetitive and cumulative radiation doses, and cost [6].
- AU of the methods described above are typically only capable of detecting CRC after the formation of an adenoma, and are generally not ideally suited for large-scale population screening. None of the above tests provide a quantitative assessment of a CRC -positive or negative promoting environment. Neither do any of the above tests provide a quantitative assessment of the effect of CRC on normal human biochemistry and related health states. Whether genomics-based tests will result in high diagnostic accuracy for sporadic CRC remains to be seen.
- Davies et al [7] outlined the features of an ideal screening test for CRC, as follows: 1) inexpensive; 2) simple to perform; 3) non-invasive; 4) represents the whole colon; 5) unambiguous interpretation of results (that is, high sensitivity, specificity, positive predictive value, and negative predictive value); 6) easy to teach; and 7) easy to maintain quality control.
- a diagnostic assay based on small molecules or metabolites in serum fulfills the above criteria, as development of assays capable of detecting specific metabolites is relatively simple and cost effective per assay. The test would be minimally invasive and would be indicative of disease status regardless of colonic proximity. Translation of the method into a clinical assay compatible with current clinical chemistry laboratory hardware would be commercially acceptable and effective, and would result in rapid deployment worldwide. Furthermore, the requirement for highly trained personnel to perform and interpret the test would be eliminated.
- CRC-specific biomarkers in human serum that could provide an assessment of CRC presence, of a CRC-promoting or inhibitory environment, of the physiological burden of CRC, or a combination of these characteristics would be extremely beneficial in the management of CRC risk, prevention, and treatment.
- a test designed to measure these biomarkers would be widely accepted by the general population as it would be minimally invasive and could possibly be used to monitor an individual's susceptibility to disease prior to resorting to, or in combination with, conventional screening methods.
- Ovarian Cancer is the fifth leading cause of cancer death among women [8]. It has been estimated that over 22,000 new cases of ovarian cancer will be diagnosed this year, with 16,210 deaths predicted in the United States alone [9]. Ovarian cancer is typically not identified until the patient has reached stage III or IV and have a poor prognosis (5 year survival of around 25- 30%) [10].
- the current screening procedures for ovarian cancer involve the combination of bimanual pelvic examination, transvaginal ultrasonography and serum CAl 25 measurements [9]. The efficacy of this screening procedure for ovarian cancer is currently of unknown benefit, as there is a lack of evidence that the screen reduces mortality rates, and it is under scrutiny for the risks associated with false positive results [8, 11]. According to the American Cancer Society CAl 25 measurement and transvaginal ultrasonography are not reliable screening or diagnostic tests for ovarian cancer, and that the only current method available to make a definite diagnosis is surgically (http://www.cancer.org).
- CA125 cancer antigen-125
- a CAl 25 test result that is higher than 30- 35U/ml is typically accepted as being at an elevated level [9].
- There have been difficulties in establishing the accuracy, sensitivity and specificity of the CAl 25 screen for ovarian cancer due to the different thresholds to define elevated CA125, varying sizes of patient groups tested, and broad ranges in the age and ethnicity of patients [8].
- CAl 25 test only returns a true positive result for ovarian cancer in roughly 50% of stage I patients and about 80% in stage II, III and IV (http://pathology2.ihu.edu). Endometriosis, benign ovarian cysts, pelvic inflammatory disease and even the first trimester of a pregnancy have been reported to increase the serum levels of CA125 [1 1].
- the National Institute of Health's website states that CA-125 is not an effective general screening test for ovarian cancer.
- a method for identifying metabolite markers for use in diagnosing CRC and OC comprising the steps of: introducing a sample from a patient presenting said disease state, said sample containing a plurality of unidentified metabolites into a high resolution mass spectrometer, for example, a Fourier Transform Ion Cyclotron Resonance Mass Spectrometer (FTMS); obtaining, identifying and quantifying data for the metabolites; creating a database of said identifying and quantifying data; comparing the identifying and quantifying data from the sample with corresponding data from a control sample; identifying one or more metabolites that differ; and selecting the minimal number of metabolite markers needed for optimal diagnosis.
- FTMS Fourier Transform Ion Cyclotron Resonance Mass Spectrometer
- a process for developing a metabolite biomarker test to diagnose a health state of an organism comprising: obtaining biological samples from organisms from a plurality of health states; introducing said biological samples into a high resolution/accurate mass mass spectrometer to obtain identifying and quantifying data on the metabolites contained within the biological samples to discover metabolites that differ in intensity between a plurality of health states; identifying the minimal set of biomarkers necessary to differentiate said health states using multivariate statistics; confirming these biomarkers using an independent MS method; and creating a targeted high throughput method for the measurement of the biomarkers identified and verified.
- a method for identifying colorectal cancer-specific metabolic markers comprising the steps of: introducing a sample from a patient diagnosed with colorectal/ovarian cancer, said sample containing a plurality of unidentified metabolites into a Fourier Transform Ion Cyclotron Resonance Mass Spectrometer (FTMS); obtaining identifying and quantifying data for the metabolites; creating a database of said identifying and quantifying data; comparing the identifying and quantifying data from the sample with corresponding data from a control sample; identifying one or more metabolites that differ; wherein the metabolites are selected from the group consisting of metabolites one or more of the metabolites shown in Table 3, or fragments or derivatives thereof.
- FTMS Fourier Transform Ion Cyclotron Resonance Mass Spectrometer
- a method for identifying colorectal cancer-specific metabolic markers comprising the steps of: introducing a sample from a patient diagnosed with colorectal/ovarian cancer, said sample containing a plurality of unidentified metabolites into a Fourier Transform Ion Cyclotron Resonance Mass Spectrometer (FTMS); obtaining identifying and quantifying data for the metabolites; creating a database of said identifying and quantifying data; comparing the identifying and quantifying data from the sample with corresponding data from a control sample; identifying one or more metabolites that differ; wherein the metabolites are selected from the group consisting of metabolites with neutral accurate masses measured in Daltons of, or substantially equivalent to, 446.3406, 448.3563, 450.3726, 464.3522, 466.3661, 468.3840, 538.4259, 592.4711, and 594.4851 and the LC-MS/MS fragment patterns shown in any one of Figures 13 to
- a method for identifying ovarian cancer-specific metabolic markers comprising the steps of: introducing a sample from a patient diagnosed for colorectal/ovarian cancer, said sample containing a plurality of unidentified metabolites into a Fourier Transform Ion Cyclotron Resonance Mass Spectrometer (FTMS); obtaining identifying and quantifying data for the metabolites; creating a database of said identifying and quantifying data; comparing the identifying and quantifying data from the sample with corresponding data from a control sample; identifying one or more metabolites that differ; wherein the metabolites are selected from the group consisting of metabolites with accurate neutral masses measured in Daltons of, or substantially equivalent to, 446.3406, 448.3563, 450.3726, 464.3522, 466.3661, 468.3840, 538.4259, 592.4711, and 594.4851 and the LC-MS/MS fragment patterns shown in any one of Figures 13 to 21
- a CRC/OC cancer-specific metabolic marker selected from the metabolites listed in Table 3 or fragments or derivatives thereof.
- a CRC/OC cancer-specific metabolic marker selected from the group consisting of metabolites with an accurate neutral mass (measured in Daltons) of, or substantially equivalent to, 446.3406, 448.3563, 450.3726, 464.3522, 466.3661, 468.3840, 538.4259, 592.4711, and 594.4851 or fragments or derivative thereof where a +/- 5 ppm difference would indicate the same metabolite.
- a colorectal/ovarian cancer-specific metabolic marker selected from the group consisting of metabolites with an accurate neutral mass measured in Daltons of, or substantially equivalent to, 446.3406, 448.3563, 450.3726, 464.3522, 466.3661, 468.3840, 538.4259, 592.4711, and 594.4851 and the LC-MS/MS fragment patterns shown in any one of Figures 13 to 21 or fragments or derivatives thereof.
- a colorectal/ovarian cancer-specific metabolic marker selected from the group consisting of metabolites with a molecular formula selected from the group consisting of: C28H46O4, C28H48O4, C28H50O4, C28H48O5, C28H50O5, C28H52O5, C32H58O6, C36H64O6 and C36H66O6.
- a method for diagnosing a patient for the presence of a colorectal or ovarian cancer or at risk of developing CRC or OC comprising the steps of: screening a sample from said patient for the presence or absence of one or more metabolic markers selected from the group consisting of metabolites listed in Table 3, or fragments or derivates thereof ,wherein a difference in intensity of one or more of said metabolic markers indicates the presence of CRC or OC
- a method for diagnosing a patient for the presence of a colorectal or ovarian cancer comprising the steps of: screening a sample from said patient for the presence or absence of one or more metabolic markers selected from the group consisting of metabolites with an accurate neutral mass of, or substantially equivalent to, 446.3406, 448.3563, 450.3726, 464.3522, 466.3661, 468.3840, 538.4259, 592.4711, and 594.4851; wherein the absence of one or more of said metabolic markers indicates the presence of CRC or OC.
- a method for diagnosing the presence or absence of CRC or OC in a test subject of unknown disease status comprising: obtaining a blood sample from said test subject; analyzing said blood sample to obtain quantifying data on molecules selected from the group comprised of molecules identified by the neutral accurate masses 446.3406, 448.3563, 450.3726, 464.3522, 466.3661, 468.3840, 538.4259, 592.4711, and 594.4851 or molecules having masses substantially equal to these molecules or fragments of derivatives thereof; comparing the quantifying data obtained on said molecules in said test subject with quantifying data obtained from said molecules from a plurality of CRC or OC-positive humans or quantifying data obtained from a plurality of CRC or OC-negative humans; and using said comparison to determine the probability that the test subject is CRC/OC positive or negative.
- the present invention also discloses the identification of vitamin E-like metabolites that are differentially expressed in the serum of CRC- and OC-positive patients versus healthy controls.
- the differential expressions disclosed are specific to CRC and OC.
- a serum test developed using an optimal subset of metabolites selected from the group consisting of vitamin E-like metabolites, can be used to diagnose CRC/OC presence, or the presence of a CRC or OC-promoting or inhibiting environment.
- a serum test developed using an optimal subset of metabolites selected from the group consisting of vitamin E-like metabolites, can be used to diagnose the CRC health-state resulting from the effect of treatment of a patient diagnosed with CRC.
- Treatment may include chemotherapy, surgery, radiation therapy, biological therapy, or other.
- a serum test developed using an optimal subset of metabolites selected from the group consisting of vitamin E-like metabolites, can be used to longitudinally monitor the CRC status of a patient on a CRC therapy to determine the appropriate dose or a specific therapy for the patient.
- the present invention also discloses the identification of gamma-tocopherol/tocotrienol metabolites in which the aromatic ring structure has been reduced that are differentially expressed in the serum of CRC- and OC-positive patients versus healthy controls.
- the differential expressions disclosed are specific to CRC and OC.
- the present invention discloses the presence of gamma-tocopherol/tocotrienol metabolites in which there exists -OC2H5, -OC4H9, or -OC8H17 moieties attached to the hydroxy chroman-containing structure in human serum.
- the present invention also discloses the identification of alpha-tocopherol metabolites that are differentially expressed in the serum of CRC- positive patients versus healthy controls.
- the differential expressions disclosed are specific to CRC.
- a method for identifying and diagnosing individuals who would benefit from anti-oxidant therapy comprising: obtaining a blood sample from said test subject; analyzing said blood sample to obtain quantifying data on all, or a subset of, tocopherols, tocotrienols, vitamin E-related metabolites or metabolic derivatives of said metabolite classes; comparing the quantifying data obtained on said molecules in said test subject with reference data obtained from the analysis of a plurality of CRC- or OC-negative humans; and using said comparison to determine the probability that the test subject would benefit from such therapy.
- a method for determining the probability that a subject is at risk of developing OC or CRC comprising: obtaining a blood sample from a CRC or OC asymptomatic subject; analyzing said blood sample to obtain quantifying data on all, or a subset of, tocopherols, tocotrienols, or metabolic derivatives of said metabolite classes; comparing the quantifying data obtained on said molecules in said test subject with reference data obtained from the analysis of a plurality of CRC- or OC-negative humans; using said comparison to determine the probability that the test subject is at risk of developing OC or CRC.
- a method for diagnosing individuals who respond to a dietary, chemical, or biological therapeutic strategy designed to prevent, cure, or stabilize CRC or OC or improve symptoms associated with CRC or OC comprising: obtaining one or more blood samples from said test subject either from a single collection or from multiple collections over time; analyzing said blood samples to obtain quantifying data on all, or a subset of, tocopherols, tocotrienols, vitamin E-like molecules, or metabolic derivatives of said metabolite classes; comparing the quantifying data obtained on said molecules in said test subject's samples with reference data obtained from said molecules from a plurality of CRC- or OC-negative humans; and using said comparison to determine whether the metabolic state of said test subject has improved during said therapeutic strategy.
- a method for identifying individuals who are deficient in the cellular uptake or transport of vitamin E and related metabolites by the analysis of serum or tissue using various strategies including, but not limited to: radiolabeled tracer studies, gene expression or protein expression analysis of vitamin E transport proteins, analysis of genomic aberrations or mutations in vitamin E transport proteins, in vivo or ex vivo imaging of vitamin E transport protein levels, antibody-based detection (enzyme-linked immunosorbant assay, ELISA) of vitamin E transport proteins.
- FIGURE 1 shows a summary of the steps involved in the identification of the CRC/OC diagnostic biomarker panel in accordance with an embodiment of the present invention
- FIGURE 2 shows the prediction of microarray analysis (PAM) training error ( Figure 2A) and cross validation misclassification error ( Figure 2B) plots.
- PAM microarray analysis
- FIGURE 3 shows the PAM output cross-validated diagnostic probabilities for all samples based on the classifier created in Figure 2.
- FIGURE 4 shows the receiver-operator characteristic curve based on cross- validated probabilities.
- FIGURE 5 shows the diagnostic predictions for blinded test samples when half the samples are used for training and the other half are used as a blinded test set.
- FIGURE 6 shows the prediction results (Figure 6A) and receiver-operator characteristic curve (Figure 6B) based on blinded test set diagnosis.
- FIGURE 7 shows the raw FTMS spectra for six of the selected biomarkers (FTMS neutral mass shown; Figures 7A to 7F). Top panel, 5 normal samples; bottom panel. 5 CRC- positive samples.
- FIGURE 8 shows the QSTAR extracted ion chromatograms for six of the biomarkers (nominal detected mass indicated; Figures 8A to 8F). Top panel, 5 normal samples; bottom panel 5 CRC-positive samples.
- FIGURE 9 shows the average extracted mass spectra for retention time window; 16-17 minutes for 5 normal (Figure 9A) and 5 CRC (Figure 9B) serum samples as detected on the QSTAR and the net difference (Figure 9C).
- FIGURE 10 shows the averaged CRC biomarker intensities of five CRC and five normal samples from FTMS ( Figure 10A) and Q-star ( Figure 10B) analysis. CRC-positive in the first column for each biomarker; normals shown in the second column for each biomarker.
- FIGURE 11 shows a graph of 30 metabolites that are part of the vitamin E-like family as detected in the FTMS dataset. These can be broken into groups depending on the numbers of carbons they contain. The intensities of gamma (GT) and alpha tocopherol (AT) are also shown.
- GT gamma
- AT alpha tocopherol
- FIGURE 12 shows the structures of gamma tocopherol and tocotrienol ( Figures 12A and 12B) and six of the C28-containing vitamin-E-like molecules ( Figures 12C to 12H) as determined by MSMS and NMR.
- FIGURE 13 shows the putative structures of key MS/MS fragments for neutral mass biomarker 448.3726 (C 28 H 48 O 4 ).
- FIGURE 14 shows the putative structures of key MS/MS fragments for neutral mass biomarker 464.3522 (C 28 H 4S O 5 ).
- FIGURE 15 shows the putative structures of key MS/MS fragments for neutral mass biomarker 446.3522 (C 28 H 46 O 4 ).
- FIGURE 16 shows the putative structures of key MS/MS fragments for neutral mass biomarker 466.3661 (C 28 H 50 O 5 ).
- FIGURE 17 shows putative structures of key MS/MS fragments for neutral mass biomarker 450.3726 (C 28 H 50 O 4 ).
- FIGURE 18 shows putative structures of key MS/MS fragments for neutral mass biomarker 468.3840 (C 28 H 52 O 5 ).
- FIGURE 19 shows putative structures of key MS/MS fragments for neutral mass biomarker 538.4259 (C 32 H 58 O 6 ).
- FIGURE 20 shows putative structures of key MS/MS fragments for neutral mass biomarker 592.4711 (C 36 H 64 O 6 )
- FIGURE 21 shows putative structures of key MS/MS fragments for neutral mass biomarker 594.4851 (C 36 H 66 O 6 ).
- FIGURE 22 shows 1 H-NMR spectra of 448.3406 (C28H48O4)
- FIGURE 23 shows 1 H-NMR analysis of 464.3522 (C28H48O5)
- FIGURE 24 shows 1 H-NMR analysis of 446.3406 (C28H46O4)
- FIGURE 25 shows 1 H-NMR analysis of 466.3661 (C28H50O5)
- FIGURE 26 shows a summary of the MS/MS high throughput screening method.
- FIGURE 27 shows Analyst screenshots of the 6 CRC biomarker transitions and internal standard transitions (Figure 27A to 27F), and housekeeping transitions (Figure 27G). Each page shows the peak areas for the transitions of two biomarkers in a typical "normal” and typical "CRC positive” individual. The top four plots are from the normal, the bottom four are from the CRC positive.
- BM biomarker
- IS internal standard.
- Figure 28 shows the normal population distribution based on the final HTS output of 288 disease-free individuals.
- the -1.3 indicates the cutoff value selected as the point below which a person would be considered high risk for CRC (see Figure 29).
- Figure 29 shows the HTS diagnostic output. Cutoff ratios based on the distribution of normal subjects, as shown in Figure 28, were selected as to achieve a specificity of 90.5%. This means that patient scores between -4 and -1.3 are high risk for CRC, scores between -1.3 and - 0.8 are medium risk, and scores greater than -0.8 are low risk. The recommended courses of actions are shown.
- FIGURE 30 shows the Gamma-tocopherol/tocotrienol neutralization of lipid peroxidation.
- the Figure shows the auto-oxidation of an unsaturated fatty acid (Figure 30A), the stabilization of peroxyl radical by gamma-tocopherol ( Figure 30B), the reaction with a peroxly radical by gamma-tocopherol radical ( Figure 30C) and the two semi-stable peroxides fromed by gamma-tocopherol ( Figure 30D).
- FIGURE 31 shows the internal degradation of gamma-tocopherol peroxide in the presence of iron.
- Figure 31 A shows the C30 series of tocopherol metabolites that arise from linolenic acid.
- Figure 31 B shows the C32 series of tocopherol metabolites that arise from linoleic acid.
- Figure 31C shows the C36 series of tocopherol metabolites that arise from oleic acid.
- FIGURE 32 shows the hydroperoxide degradation in the presence of iron.
- FIGURE 33 shows the spontaneous break down of free radicals.
- Figure 33 A shows the short-chain alkane radical and long-chain aldehyde which results from breakdown at the bond indicated by the dotted line "A”
- Figure 33B shows the short-chain aldehyde and long-chain alkane radical that would result from spontaneous breakdown at bond "B" (dotted line B).
- FIGURE 34 shows that gamma-tocopherol can neutralize the free alkane radical.
- the unhindered aromatic ring structure of gamma-tocopherol/tocotrienol can accept a hydrogen radical from the radical alkane, resulting in a ring-stabilized tocopherol/tocotrienol radical and a stable alkene (Figure 34A).
- This hydrogen radical acceptance reaction can occur four times, reducing the ring structure to a single double bond ( Figure 34B).
- FIGURE 35 shows the omega carboxylation resulting from liver P450 metabolism.
- FIGURE 36 shows a hypothesis for the role of vitamin E and related metabolites in a normal state ( Figure 36A) and in CRC and OC ( Figure 36B).
- the present invention relates to the diagnosis of colorectal and ovarian cancers (CRC and OC, respectively).
- CRC and OC colorectal and ovarian cancers
- the present invention describes the relationship between endogenous small molecules and CRC or OC.
- the present invention relates to the diagnosis of CRC and OC through the measurement of vitamin E isoforms and related metabolites. More specifically, the present invention relates to the relationship between vitamin E-related metabolites in human serum and the implications thereof in CRC and OC.
- the present invention discloses for the first time clear and unambiguous biochemical changes specifically associated with CRC. These findings also imply that the measurement of these biomarkers may provide a universal means of measuring the effectiveness of CRC therapies. This would dramatically decrease the cost of performing clinical trials as a simple biochemical test can be used to assess the viability of new therapeutics. Furthermore, one would not have to wait until the tumor progresses or until the patient dies to determine whether the therapy provided any benefit. The use of such a test would enable researchers to determine in months, rather than years, the effectiveness of dose, formulation, and chemical structure modifications of CRC therapies.
- the present invention relates to a method of diagnosing CRC or OC by measuring the levels of specific small molecules present in human serum and comparing them to "normal" reference levels.
- a novel method for the early detection and diagnosis of CRC or OC and the monitoring the effects of treatment on CRC and OC is described.
- the preferred method involves the use of a high-throughput screening (HTS) assay developed from a subset of metabolites selected from Table 3 for the diagnosis of one or more diseases or particular health-states.
- HTS high-throughput screening
- Biological samples taken from the patients in a particular health-state category can then be compared to the same samples taken from the normal population to identify differences between the two groups, by extracting the samples and analyzing using various analytical platforms including, but not limited to, Fourier transform ion cyclotron resonance mass spectrometry (FTMS) and liquid chromatography mass spectrometry (LC-MS).
- FTMS Fourier transform ion cyclotron resonance mass spectrometry
- LC-MS liquid chromatography mass spectrometry
- the biological samples could originate from anywhere within the body, including, but not limited to, blood (serum/plasma), cerebrospinal fluid (CSF), urine, stool, breath, saliva, or biopsy of any solid tissue including tumor, adjacent normal, smooth and skeletal muscle, adipose tissue, liver, skin, hair, kidney, pancreas, lung, colon, stomach, or other.
- serum samples were obtained from representative populations of healthy CRC- and OC-negative individuals, and of professionally diagnosed CRC -positive patients.
- serum will be used, but it will be obvious to those skilled in the art that plasma, whole blood, or a sub- fraction of whole blood may be used in the method.
- a blood sample is drawn from a patient there are several ways in which the sample can be processed.
- the range of processing can be as little as none (i.e. frozen whole blood) or as complex as the isolation of a particular cell type.
- the most common and routine procedures involve the preparation of either serum or plasma from whole blood. All blood sample processing methods, including spotting of blood samples onto solid-phase supports, such as filter paper or other immobile materials, are also contemplated by the invention.
- the processed blood sample described above is then further processed to make it compatible with the analytical analysis technique to be employed in the detection and measurement of the biochemicals contained within the processed blood sample (in our case, a serum sample).
- the types of processing can range from as little as no further processing to as complex as differential extraction and chemical derivatization.
- Extraction methods include, but are not limited to, sonication, soxhlet extraction, microwave assisted extraction (MAE), supercritical fluid extraction (SFE), accelerated solvent extraction (ASE), pressurized liquid extraction (PLE), pressurized hot water extraction (PHWE), and/or surfactant-assisted extraction in common solvents such as methanol, ethanol, mixtures of alcohols and water, or organic solvents such as ethyl acetate or hexane.
- the preferred method of extracting metabolites for FTMS non-targeted analysis is to perform a liquid/liquid extraction whereby non-polar metabolites dissolve in an organic solvent and polar metabolites dissolve in an aqueous solvent.
- the metabolites contained within the serum samples were separated into polar and non-polar extracts by sonication and vigorous mixing (vortex mixing).
- Extracts of biological samples are amenable to analysis on essentially any mass spectrometry platform, either by direct injection or following chromatographic separation.
- Typical mass spectrometers are comprised of a source, which ionizes molecules within the sample, and a detector for detecting the ionized particles.
- sources include electron impact, electrospray ionization (ESI), atmospheric pressure chemical ionization (APCI), matrix assisted laser desorption ionization (MALDI), surface enhanced laser desorption ionization (SELDI), and derivations thereof.
- Common ion detectors can include quadrupole- based systems, time-of-flight (TOF), magnetic sector, ion cyclotron, and derivations thereof.
- the small molecules are identified by a method known as non-targeted analysis.
- Non-targeted analysis involves the measurement of as many molecules in a sample as possible, without any prior knowledge or selection of the components prior to the analysis (see WO 01/57518, published August 9, 2001). Therefore, the potential for non-targeted analysis to discover novel metabolite biomarkers is high versus targeted methods, which detect a predefined list of molecules.
- the present invention uses a non-targeted method to identify metabolite components that differ between CRC -positive and healthy individuals, followed by the development of a high- throughput targeted assay for a subset of the metabolites identified from the non-targeted analysis.
- colorectal cancer-specific metabolic markers selected from the group consisting of metabolites with an accurate neutral mass (measured in Daltons) of, or substantially equivalent to, 446.3406, 448.3563, 450.3726, 464.3522, 466.3661, 468.3840, 538.4259, 592.4711, and 594.4851 where a +/- 5 ppm difference would indicate the same metabolite, were identified. These markers can thus be used in a diagnostic test to screen patients for the presence of CRC.
- HTS high-throughput screening
- the HTS assay is based upon conventional triple-quadrupole mass spectrometry technology (See Figure 26 for summary).
- the HTS assay works by directly injecting a serum extract into the triple-quad mass spectrometer, which then individually isolates each of the six parent molecules by single- ion monitoring (SIM). This is followed by the fragmentation of each molecule using an inert gas (called a collision gas, collectively referred to collision-induced dissociation or CID). The intensity of a specific fragment from each parent biomarker is then measured and recorded, through a process called multiple-reaction monitoring (MRM).
- SIM single- ion monitoring
- CID collision-induced dissociation
- MRM multiple-reaction monitoring
- an internal standard molecule is also added to each sample and subject to fragmentation as well. This internal standard fragment should have the same intensity in each sample if the method and instrumentation is operating correctly.
- a ratio of the biomarker to IS fragment intensities are calculated, and the ratios log- transformed. The lowest value of the six for each patient sample is then compared to a previously determined distribution of disease-positive and controls, to determine the relative likelihood that the person is positive or negative for the disease.
- vitamin E collectively refers to eight naturally occurring isoforms, four tocopherols (alpha, beta, gamma, and delta) and four tocotrienols (alpha, beta, gamma, and delta).
- the predominant form found in western diets is gamma-tocopherol whereas the predominant form found in human serum/plasma is alpha-tocopherol.
- Tocotrienols are also present in the diet, but are more concentrated in cereal grains and certain vegetable oils such as palm and rice bran oil. Interestingly, it is suggested that tocotrienols may be more potent than tocopherols in preventing cardiovascular disease and cancer [14].
- Plasma concentrations of the tocopherols are believed to be tightly regulated by the hepatic tocopherol binding protein. This protein has been shown to preferentially bind to alpha-tocopherol [19]. Large increases in alpha-tocopherol consumption result in only small increases in plasma concentrations [20]. Similar observations hold true for tocotrienols, where high dose supplementation has been shown to result in maximal plasma concentrations of approximately only 1 to 3 micromolar [21].
- Birringer et al [17] showed that although upwards of 50% of ingested gamma-tocopherol is metabolized by human hepatoma HepG2 cells by omega-oxidation to various alcohols and carboxylic acids, less than 3% of alpha-tocopherol is metabolized by this pathway. This system appears to be responsible for the increased turnover of gamma-tocopherol. In this paper, they showed that the creation of the omega COOH from gamma-tocopherol occured at a rate of >50X than the creation of the analogous omega COOH from alpha-tocopherol. Birringer also showed that the trienols are metabolized via a similar, but more complex omega carboxylation pathway requiring auxiliary enzymes [17].
- the alpha and gamma tocotrienols were also not detected in the serum of patients used in the studies reported in this work, suggesting that the primary purpose of the gamma- tocopherol/trineol-specific P450 omega hydroxylase is the formation of the omega COOH and not gamma-CEHC.
- the various gamma-tocopherol/tocotrienol omega COOH metabolites disclosed in the present application are novel bioactive agents and that they perform specific and necessary biological functions for the maintenance of normal health and for the prevention of disease.
- alpha tocopherol and alpha tocotrienol include the ability of alpha tocotrienol to specifically prevent neurodegeneration by regulating specific mediators of cell death [26], the ability of trienols to lower cholesterol [27], the ability to reduce oxidative protein damage and extend life span of C.elegans [28], and the ability to suppress the growth of breast cancer cells [29, 30].
- novel gamma- tocopherol/tocotrienol metabolites in human serum have had the aromatic ring structure reduced.
- the gamma-tocopherol/tocotrienol metabolites comprise -OC2H5, -OC4H9, or -OC8H17 moieties attached to the hydroxychroman structure in human serum.
- the present invention discloses a hypothesis as to how gamma-tocopherol/tocotrienol can react with alkane radicals to create a stable alkene and a stabilized gamma-tocopherol/tocotrienol radical. It is suggested that, through this mechanism, one molecule of gamma-tocopherol/tocotrienol can neutralize up to six alkane radicals.
- the present invention further suggests how a gamma-tocopherol/tocotrienol radical can react with a lipid peroxide and subsequently neutralize the lipid peroxide into a stable gamma- tocopherol/tocotrienol alkyl ether and a stable lipid aldehyde. It is also suggested that the presence of iron may catalyze this reaction.
- tissues that are primarily fed by the blood supply are preferentially enriched with alpha-tocopherol [18] whereas colon epithelial cells, which absorb tocopherols directly from the large intestine have concentrations representative of the dietary ratio of these isoforms [34].
- the present application discloses that alpha-tocopherol/tocotrienol concentrations are significantly decreased in the serum of CRC patients versus controls but not in OC, prostate, renal cell, breast, or lung cancers. It is further disclosed that gamma-tocopherol and gamma- tocopherol/tocotrienol-related metabolite intensities are significantly decreased in the serum of CRC and OC patients versus controls but not in prostate, renal cell, breast, or lung cancers.
- novel metabolites disclosed herein are indicators of vitamin E activity and that the decrease of such metabolites is indicative of one of the following situations:
- the accurate neutral masses of the nine metabolites (M-H ions converted to neutral mass) specific to CRC pathology were determined by FTICR-MS to be 446.3406, 448.3563, 450.3726, 464.3522, 466.3661, 468.3840, 538.4259, 592.4711, and 594.4851. Based on these accurate neutral mass values, the molecular formulas of the nine preferred diagnostic markers were determined to be C28H46O4, C28H48O4, C28H50O4, C28H48O5, C28H50O5, C28H52O5, C32H58O6, C36H64O6, C36H66O6, respectively.
- the M-H ions of these metabolites are characterized as having a collision induced dissociation (CID) MS/MS fragmentation pattern comprising one or more than one of the daughter ions shown in Figures 13 to 21. More particularly, the M-H ions of these seven metabolites are characterized in having a collision induced dissociation (CID) MS/MS fragmentation pattern comprising each of the daughter ions shown in Figures 13 to 21.
- CID collision induced dissociation
- Example 1 Discovery and identification of differentially expressed metabolites in CRC-positive versus normal healthy controls
- the biochemical markers of CRC described in the invention were derived from the analysis of 40 serum samples from CRC-positive patients (24 TNM stage I/II and 16 stage III/IV) and 50 serum samples from healthy controls. All samples were single time-point collections, and the CRC samples were taken either immediately prior to or immediately following surgical resection of a tumor. All samples were taken prior to chemo- or radiation therapy.
- the invention described herein involved the analysis of serum extracts from 90 individuals (40 CRC, 50 normal) by direct injection into an FTMS and ionization by either ESI or APCI, in both positive and negative modes.
- FTMS over other MS-based platforms is the high resolving capability that allows for the separation of metabolites differing by only hundredths of a Dalton, many of which would be missed by lower resolution instruments.
- Samples were directly injected using ESI and APCI at a flow rate of 600 ⁇ L per hour.
- Ion transfer/detection parameters were optimized using a standard mix of serine, tetra-alanine, reserpine, Hewlett-Packard tuning mix and the adrenocorticotrophic hormone fragment 4-10.
- the instrument conditions were tuned to optimize ion intensity and broad-band accumulation over the mass range of 100- 1000 amu according to the instrument manufacturer's recommendations. A mixture of the abovementioned standards was used to internally calibrate each sample spectrum for mass accuracy over the acquisition range of 100-1000 amu.
- a self-generated two-dimensional (mass vs. sample intensity) array was then created using DISCOVAmet ⁇ csTM software (Phenomenome Discoveries Inc., Saskatoon, SK, Canada). The data from multiple files were integrated and this combined file was then processed to determine all of the unique masses. The average of each unique mass was determined, representing the y-axis. A column was created for each file that was originally selected to be analyzed, representing the x-axis. The intensity for each mass found in each of the files selected was then filled into its representative x,y coordinate. Coordinates that did not contain an intensity value were left blank. Once in the array, the data were further processed, visualized and interpreted, and putative chemical identities were assigned.
- Each of the spectra were then peak picked to obtain the mass and intensity of all metabolites detected. These data from all modes were then merged to create one data file per sample. The data from all 90 samples were then merged and aligned to create a two-dimensional metabolite array in which each sample is represented by a column and each unique metabolite is represented by a single row. In the cell corresponding to a given metabolite sample combination, the intensity of the metabolite in that sample is displayed. When the data is represented in this format, metabolites showing differences between groups of samples (i.e., normal and cancer) can be determined.
- ANNs artificial neural networks
- SVMs support vector machines
- PLSDA partial least squares discriminant analysis
- PCA supervised principal component analysis
- shrunken centroids described here
- the graph in Figure 2 A shows the number of metabolites required to achieve given training errors at various threshold values (a user-definable PAM parameter).
- the plot shows that a training classifier with less than 10% error rate (0.1 training error) is possible with as few as 7 metabolite features (threshold value of approximately 5.8, see arrow). It is worthwhile to note that the lowest training error can be achieved using 300 or greater metabolite features, however, the error is only a few percent lower than using 7 metabolite features, and using hundreds of features would be impractical for clinical utility.
- the plot in Figure 2B is conceptually similar to that in 2A, however, the graph in 2B shows the misclassification error of the trained classifier for CRC and normal individuals following the cross-validation procedure integral to the PAM program.
- the line connected by diamonds mirrors the previous result, showing that minimal cross-validated misclassification error for CRC -positive individuals can be achieved using as few as seven metabolites.
- normal individuals, depicted by the squares can be accurately diagnosed as normal using only one metabolite feature, but at this threshold, the misclassification error for CRC is greater than 95% (see arrows). Therefore, the best combination of metabolite features based on this method, which can both positively and negatively diagnose CRC comprises a combination of seven metabolite features.
- Figure 5 The predicted probabilities of the blinded test samples as either being CRC-positive or normal are plotted in Figure 5.
- the results show that two of the CRC-positive samples are given a higher probability of being normal, and two of the normals are given a higher probability of being CRC-positive.
- Figure 6A lists the patients, which were used in the test set, and their actual and predicted diagnosis. The probabilities from Figure 5 were then translated into a ROC curve, as shown in Figure 6B.
- the performance characteristics based on classification of the blinded test set were sensitivity of 91%, specificity of 92.6%, and overall diagnostic accuracy of 91.8%.
- Eluate from the HPLC was analyzed using an ABI QSTAR® XL mass spectrometer fitted with an atmospheric pressure chemical ionization (APCI) source in negative mode.
- the scan type in full scan mode was time-of-flight (TOF) with an accumulation time of 1.0000 seconds, mass range between 50 and 1500 Da, and duration time of 55 min.
- Source parameters were as follows: Ion source gas 1 (GSl) 80; Ion source gas 2 (GS2) 10; Curtain gas (CUR) 30; Nebulizer Current (NC) -3.0; Temperature 400 0 C; Declustering Potential (DP) -60; Focusing Potential (FP) -265; Declustering Potential 2 (DP2) -15.
- scan type was product ion
- accumulation time was 1.0000 seconds
- scan range between 50 and 650 Da
- CE collision energy
- CAD collision gas
- Figure 9 shows three sets of extracted mass spectra (EMS) for six of the metabolites at a retention time window of 16- 17 minutes.
- Figure 9A represent the average EMS of the five normal samples
- Figure 9B represents the average EMS for the five CRC samples.
- Figure 9C shows the net difference between the top two spectra. As can be seen, all peaks in the mass range between approximately 445 and 600 Da are barely detectable in the CRC panel (boxed region). All seven of the biomarkers identified on the FTMS platform were detected on the Q-Trap, and were seven of the most abundant peaks in this mass range (highlighted by arrows).
- Example 3 Structure elucidation of the primary metabolite biomarkers
- the molecular formulas of the nine preferred diagnostic markers were determined to be C28H46O4, C28H48O4, C28H50O4, C28H48O5, C28H50O5, C28H52O5, C32H58O6, C36H64O6, C36H66O6 based on their accurate neutral mass, polarity, and ionization characteristics.
- These metabolites have been determined, according to the present invention to consist of a semi- saturated chroman ring and phytyl side chain and therefore consistent with vitamin E-related structures.
- the conditions of extraction also provide insights about the chemical properties of the biomarkers. All seven of the metabolite markers were extracted into an organic ethyl acetate fraction, indicating that these metabolites are non-polar under acidic condition. Furthermore, they were preferentially ionized in negative APCI mode indicating an acidic proton is present in the molecules.
- the structure of a given molecule will dictate a specific fragmentation pattern under defined conditions that is specific for that molecule (equivalent to a person's fingerprint). Even slight changes to the molecule's structure can result in a different fragmentation pattern.
- the fragments generated by CID can be used to gain insights about the structure of a molecule. MS/MS analysis was carried out on the ABI- QSTAR® XL with all parameters as previously mentioned using nitrogen as the collision gas at 5 psi and CE settings of -25, -35 and -50 volts.
- the C32 and C36 biomarkers were subsequently hypothesized to be metabolic byproducts resulting from the reaction of gamma- tocopherol and the lipid peroxides of linoleic and oleic acid residues, respectively ( Figures 19 to 21).
- the MS/MS spectra support this hypothesis.
- minor modifications including, but not limited to, the location of a double bond, the location of a hydroxyl group, the stereo or chiral orientation of certain carbon atoms
- the assignment of the structures to fragments are shown in Figures 13 to 21, and listed in Tables 5 to 10 for six of the markers further characterized below.
- M-I masses The masses reported for MS-MS results refer to the detected mass, and not the neutral mass. These are referred to as M-I masses, and will appear to lack one Dalton in mass or a hydrogen within the formula relative to their neutral counterparts mentioned in the previous sections, because they are detected in a negative ionization mode on the mass spectrometer. However, M-I masses represent the same molecules as the neutral counterparts. The subsequent NMR section refers to neutral masses.
- MS/MS data obtained in the negative ionization mode for each biomarker was individually analyzed for structural assignment, particularly the placement of functional groups.
- the MS/MS spectra of each biomarker showed peaks due to loss of water (M- 18) and carbon dioxide (M-44). These stipulate the presence of free hydroxyl groups adjacent to a tertiary or secondary carbon molecule and a carboxylic acid group. Loss of the phytol chain fragment was also commonly observed but cleavage of the chain occurred at different places.
- Sequential ring opening at O1-C9 is indicative in here too, followed by the cleavage between Cl 8- C19 generating a fragment Of C 22 H 35 O (m/z 315). Subsequent signal corresponding to m/z 297 (C 22 H 33 ), representing a loss of a water molecule from the open ring fragment was also observed. Unlike in biomarker 3 (m/z 448.3726) the cleavage of the phytol chain takes place at C 12-Cl 3 where the signals for the two halves of the molecules, m/z 241 (C 14 H 25 O 3 ), 223 (Ci 4 H 23 O 2 ) were observed in the MS/MS spectra of C28H48O5. This particular fragmentation is a strong evidence for the distribution of the functional groups between the chroman ring and the phytol chain.
- Ci 4 H 2 [O (m/z 205) is also observed and is also representative as the parent ion of next two consecutive fragments, m/z 177 (C 12 H 17 O) and 162 (C n Hi 14 O) indicating losses Of C 2 H 8 and CH 3 respectively.
- Cleavage of the phytol ring takes place at two positions, between C 15-Cl 6 (m/z 281; Ci 8 H 33 O 2 ) and between C 16-Cl 7 followed by a loss of water molecule (m/z 277; C 19 H 33 O). These fragments establish the absence of a hydroxyl group in the phytol chain and the unsaturation between C 17-Cl 8.
- the structure of biomarker 7 is assembled accordingly.
- Fragment due to the cleavage of the phytol chain at C15-C16 was observed as the parent ion for the next two consecutive fragments, resulted due to loss of a water molecule (m/z 169; Ci 0 Hi 7 O 2 ) and an ethylene fragment (m/z 141; C 8 Hi 3 O 2 ) respectively from C 10 Hi 9 O 3 .
- Preparative thin layer chromatography was performed on silica gel plates (EM science, 60 F 254 20 x 20 cm, 0.25 mm thickness). Compounds were visualized under UV light and in iodine.
- HPLC analysis were carried out with a high performance liquid chromatograph equipped with quaternary pump, automatic injector, degasser, and a Hypersil ODS column (5 ⁇ m particle size silica, 4.6 i.d x 200 mm) and semi-prep column (5 ⁇ m particle size silica, 9.1 i.d x 200 mm), with an inline filter.
- Mobile phase linear gradient H 2 O-MeOH to 100% MeOH in a 52 min period at a flow rate 1.0 ml/min.
- TLC R f 0.81 (cyclohexane-CH 2 Ci 2 -EtOAc, 10:4:1); for 1 H and 13 C NMR spectra, see Tables 11 and 12; FTIR (cm “1 ) 3315 (br), 2935, 2852, 1741, 1465, 1377, 1178, 726; HRAPCI-MS m/z: measured 447.3490 ([M - H] " , calcd. 447.3480 for C 28 H 47 O 4 ). MS/MS m/z (relative intensity): 447 ([M - H] " , 50%), 429 (45%), 403 (100%), 385 (20%), 279 (10%).
- TLC Rf 0.79 (cyclohexane-CH 2 Cl 2 -EtOAc, 10:4:1, UV active spot); for 1 H and 13 C NMR spectra, see Tables 11 and 12; FTIR (cm “1 ) 3125 (br), 2941, 2855, 1736, 1556, 1466, 1377, 1177, 1008, 773; HRAPCI-MS m/z: measured 445.3333 ([M-H] " , calcd. 445.3323 for C 28 H 45 O 4 ). MS/MS m/z (relative intensity): 445 ([M - H] " , 100%), 427 (60%), 401 (85%), 383 (40%), 223 (12%), 205 (20%), 177 (10%), 162 (18%).
- TLC Rf 0.62 (cyclohexane-CH 2 CI 2 -EtOAc, 10:4:1, UV active spot); for 1 H and
- Serum samples are extracted as described for non-targeted FTMS analysis.
- the ethyl acetate organic fraction is used for the analysis of each sample.
- 15uL of internal standard is added (lng/mL of (24- 13 C)-Cholic Acid in methanol) to each sample aliquot of 12OuL ethyl acetate fraction for a total volume of 135uL.
- the autosampler injects lOOuL of the sample by flow-injection analysis into the 4000QTRAP.
- the carrier solvent is 90%methanol:10%ethyl acetate, with a flow rate of 360uL/min into the APCI source.
- the MS/MS HTS method was developed on a quadrupole linear ion trap ABI 4000QTrap mass spectrometer equipped with a Turbo VTM source with an APCI probe.
- the source gas parameters were as follows: CUR: 10.0, CAD: 6, NC: -3.0, TEM: 400, GSl : 15, interface heater on.
- "Compound” settings were as follows: entrance potential (EP): -10, and collision cell exit potential (CXP): -20.0.
- the method is based on the multiple reaction monitoring (MRM) of one parent ion transition for each metabolite, one transition for the endogenous housekeeper and a single transition for the internal standard.
- MRM multiple reaction monitoring
- Each of the transitions is monitored for 250 ms for a total cycle time of 2.3 seconds.
- the total acquisition time per sample is approximately 1 min.
- a summary of the overall method is shown in Figure 26. Briefly, the method measures the intensities of each of the six biomarker and internal standard (IS) transitions (as shown in Figures 27A to 27F), as well as a "housekeeping" biomarker transition (Figure 27G) previously determined to be endogenously present in human serum.
- the housekeeping biomarker is a metabolite that was identified to not change with disease state, and should be detected in any correctly prepared serum sample. The objective of the "housekeeping" biomarker is therefore to ensure that samples collected from multiple sites are compatible with the HTS test.
- a patient score is then generated by determining the lowest mean-normalized log(2) transformed ratio of the six measured biomarker :IS transitions per patient. This value is then compared to a distribution of scores generated from normal individuals, and a CRC risk factor is assigned accordingly.
- the ABI 4000QTrap was capable of accurately measuring the transition peak areas using the method described above by plotting the peak area ratios of the biomarker transitions versus the internal standard transitions for each of the six biomarkers as well as the housekeeping metabolite ( Figure 26).
- the HTS method also incorporates a series of dilutions of reference serum material, which allows for the determination and assurance of instrument linearity. If the housekeeping metabolite is not detected, or the calibration curve has a R 2 value >0.98, then the sample run is considered a failure and the sample needs to be rerun.
- the present invention discloses a hypothesis ( Figure 36) implicating the role of vitamin E and related metabolites in the establishment and progression of CRC and OC by contemplating that the decreased levels of specific fatty acids, vitamin E isoforms, and related metabolites are not the result of a simple dietary deficiency, but rather an impairment in the colonic epithelial uptake of vitamin E and related molecules. This impairment represents a rate-limiting step for the sufficient provision of antioxidant capacity under normal or elevated oxidative stress loads.
- the initiating event for the development of CRC or OC is a lack of vitamin E gamma in colonic epithelial cells.
- antioxidants are consumed over the course of their function and that this function operates in real time; that is, excess antioxidant capacity on one day does not make up for deficient antioxidant capacity on another day.
- antioxidants have a limited capacity and shelf life and, once they are used up, oxidation reactions proceed unchecked. For this reason, the selection of antioxidant molecules that are capable of neutralizing multiple free radical molecules would be biologically favored.
- a mechanism whereby a single gamma-tocopherol/tocotrienol molecule can neutralize up to six free radical molecules is proposed and supported by the analytical data and previous literature surrounding free radical propagation.
- Figure 30 illustrates the process of auto-oxidation of an unsaturated fatty acid (linolenic acid is used as an example). Briefly, a hydrogen radical is abstracted from a hydrocarbon molecule (Figure 30A). This abstraction, mediated by light, heat, irradiation, metal ions, or radicals, is heavily favored in unsaturated hydrocarbons versus saturated hydrocarbons. In biological systems the formation of peroxide is the initiating step ( Figure 30A).
- the peroxide radical can then be either a) stabilized by gamma-tocopherol-hydroxide ( Figure 30B) or b) it can react with a gamma-tocopherol peroxide radical (Figure 30C), in both cases forming semi-stable peroxides.
- the two peroxides are then converted to a hydroxide radical through the iron-catalyzed Fenton reaction [36] or in an iron-independent fashion through nitric oxide [57], [58].
- the iron concentration in the gastrointestinal tract is substantially higher in the colon relative to the small intestine. It has been estimated that iron concentrations in the colon are greater than 10 times those found in other tissues [36]. Therefore, free radical formation in the colon is most likely an iron-catalyzed event.
- the hydroxyl radical abstracts a hydrogen radical to form a stable molecule of water and leaves behind a lipid radical. All tocopherols and tocotrienols can neutralize these hydroxyl radicals, thereby preventing lipid free radical formation. However, once a lipid radical is formed, the activity of an antioxidant is related to its ability to be co-localized with the lipid radical. It has been shown that the vitamin E isoforms contain the optimal phytyl side chain length for incorporation into lipid membranes, making these molecules ideal for scavenging lipid radicals from membranes.
- Lipid free radicals that are not scavenged readily react with oxygen to form a lipid peroxide radical (Figure 30A).
- Tocopherols/tocotrienols can donate a hydrogen radical to a lipid peroxide, resulting in the formation of a tocopherol/tocotrienol radical that is stabilized by the chromanin ring structure and a resulting lipid hydroperoxide ( Figure 30B).
- the tocopherol/tocotrienol radical is capable of reacting with a second lipid peroxide radical to form a tocopherol/tocotrienol peroxide, which is an even electron molecule (Figure 30C).
- hydro/alkyl peroxide molecules are not free radicals, the 0-0 bond is high energy, the breakdown of which is energetically favored ( Figure 30D).
- the two most potent catalysts known to facilitate the breakdown of hydroperoxides are copper and iron.
- the large intestine is a particularly concentrated source of iron. Therefore, these hydroperoxides can be broken down into a hydroxyl radical and a lipid oxide radical, thereby restarting the free radical propagation sequence.
- the tocopherol/tocotrienol peroxide is presumed to be sensitive to breakdown in the presence of iron or copper.
- the present invention proposes a novel mechanism for the internal degradation of this peroxide into a stable tocopherol/tocotrienol alkyl ether and lipid aldehyde.
- the proposed reaction creates two thermodynamically stable products. It is proposed that the peroxides formed from three primary unsaturated fatty acid residues present in endogenous lipids - linolenic, linoleic, and oleic acid - are neutralized by tocopherols/tocotrienols by this mechanism ( Figure 31 A to C).
- Table 13 A. Summary of HTS results including cross-cancer specificities, demographic and disease staging data. B. P-values showing no statistical significance between randomly selected sets of patients based on ethnicity, gender, age, BMI, presence of polyps and staging.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring And Recording Apparatus For Diagnosis (AREA)
Abstract
Description
Claims
Priority Applications (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11/910,942 US20080255764A1 (en) | 2005-09-12 | 2006-09-12 | Methods for the Diagnosis of Colorectal Cancer and Ovarian Cancer by the Measurement of Vitamin E-Related Metabolites |
EP06817639A EP1931995A4 (en) | 2005-09-12 | 2006-09-12 | Methods for the diagnosis of colorectal cancer and ovarian cancer health states |
CA2619732A CA2619732C (en) | 2005-09-12 | 2006-09-12 | Methods for the diagnosis of colorectal cancer and ovarian cancer health states |
AU2006291988A AU2006291988B2 (en) | 2005-09-12 | 2006-09-12 | Method for the diagnosis of colorectal cancer and ovarian cancer by the measurement of vitamin E-related metabolites |
EP16187670.1A EP3165925B1 (en) | 2005-09-12 | 2006-09-12 | Methods for the diagnosis of colorectal cancer |
JP2008529437A JP5038311B2 (en) | 2005-09-12 | 2006-09-12 | Method for diagnosing colorectal cancer and ovarian cancer by measuring vitamin E-related metabolites |
US15/192,522 US10697969B2 (en) | 2005-09-12 | 2016-06-24 | Methods for diagnosing a colorectal cancer (CRC) health state or change in CRC health state, or for diagnosing risk of developing CRC or the presence of CRC in a subject |
US16/879,155 US20210041444A1 (en) | 2005-09-12 | 2020-05-20 | Methods for diagnosing a colorectal cancer (crc) health state or change in crc health state, or for diagnosing risk of developing crc or the presence of crc in a subject |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US71631005P | 2005-09-12 | 2005-09-12 | |
US60/716,310 | 2005-09-12 | ||
US80476406P | 2006-06-14 | 2006-06-14 | |
US60/804,764 | 2006-06-14 |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/910,942 A-371-Of-International US20080255764A1 (en) | 2005-09-12 | 2006-09-12 | Methods for the Diagnosis of Colorectal Cancer and Ovarian Cancer by the Measurement of Vitamin E-Related Metabolites |
US15/192,522 Continuation US10697969B2 (en) | 2005-09-12 | 2016-06-24 | Methods for diagnosing a colorectal cancer (CRC) health state or change in CRC health state, or for diagnosing risk of developing CRC or the presence of CRC in a subject |
Publications (3)
Publication Number | Publication Date |
---|---|
WO2007030928A2 true WO2007030928A2 (en) | 2007-03-22 |
WO2007030928A3 WO2007030928A3 (en) | 2007-05-03 |
WO2007030928A8 WO2007030928A8 (en) | 2007-06-14 |
Family
ID=37865285
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CA2006/001502 WO2007030928A2 (en) | 2005-09-12 | 2006-09-12 | Method for the diagnosis of colorectal cancer and ovarian cancer by the measurement of vitamin e-related metabolites |
Country Status (8)
Country | Link |
---|---|
US (2) | US10697969B2 (en) |
EP (2) | EP1931995A4 (en) |
JP (1) | JP5038311B2 (en) |
KR (1) | KR20080049821A (en) |
AU (1) | AU2006291988B2 (en) |
CA (3) | CA2619732C (en) |
SG (2) | SG182169A1 (en) |
WO (1) | WO2007030928A2 (en) |
Cited By (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20090159793A1 (en) * | 2007-12-21 | 2009-06-25 | Hanas Jay S | Identification of biomarkers in biological samples and methods of using same |
EP2279417A1 (en) * | 2008-05-28 | 2011-02-02 | Georgia Tech Research Corporation | Metabolic biomarkers for ovarian cancer and methods of use thereof |
WO2013038371A1 (en) * | 2011-09-14 | 2013-03-21 | Basf Se | Means and methods for assessing gonadal toxicity |
EP2644588A2 (en) | 2006-05-26 | 2013-10-02 | Phenomenome Discoveries Inc. | Biomarkers for diagnosing multiple sclerosis, and methods thereof |
EP2682746A2 (en) | 2007-02-01 | 2014-01-08 | Phenomenome Discoveries Inc. | Methods for the diagnosis of ovarian cancer health states and risk of ovarian cancer health states |
US8993623B2 (en) | 2007-02-08 | 2015-03-31 | Phenomenome Discoveries Inc. | Method for lowering cholesterol |
US9599618B2 (en) | 2006-12-21 | 2017-03-21 | Ajinomoto Co., Inc. | Method, apparatus, system, program, and computer-readable recording medium for evaluating colorectal cancer |
US9689874B2 (en) | 2015-04-10 | 2017-06-27 | Applied Proteomics, Inc. | Protein biomarker panels for detecting colorectal cancer and advanced adenoma |
WO2018067434A1 (en) * | 2016-10-03 | 2018-04-12 | Lincoln Memorial University | Identification and use of very long chain dicarboxylic acids for disease diagnosis, chemoprevention, and treatment |
US10006925B2 (en) | 2016-05-30 | 2018-06-26 | Universal Diagnostics, S. L. | Methods and systems for metabolite and/or lipid-based detection of colorectal cancer and/or adenomatous polyps |
US10024857B2 (en) | 2009-10-01 | 2018-07-17 | Med-Life Discoveries Lp | Serum-based biomarkers of pancreatic cancer and uses thereof for disease detection and diagnosis |
WO2018227306A1 (en) * | 2017-06-15 | 2018-12-20 | Med-Life Discoveries Lp | Dicarboxylic fatty acid dimers, and derivatives thereof, as standards for quantifying levels in biospecimens |
US10867706B2 (en) | 2010-07-20 | 2020-12-15 | Applied Invention, Llc | Multi-scale complex systems transdisciplinary analysis of response to therapy |
US11073522B2 (en) | 2016-10-03 | 2021-07-27 | Lincoln Memorial University | Structural validation of very long chain dicarboxylic acids |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA3025123C (en) | 2010-05-21 | 2022-10-11 | The Governors Of The University Of Alberta | Methods for the assessment of colorectal cancer and colorectal polyps by measurement of metabolites in urine |
US11840720B2 (en) | 2019-12-23 | 2023-12-12 | Metabolomic Technologies Inc. | Urinary metabolomic biomarkers for detecting colorectal cancer and polyps |
CN113711044B (en) * | 2019-12-28 | 2022-04-12 | 中精普康(北京)医药科技有限公司 | Biomarker for detecting colorectal cancer or adenoma and method thereof |
Family Cites Families (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4978852A (en) | 1988-09-08 | 1990-12-18 | Cornell Research Foundation, Inc. | Hadamard transform measurement of MSN Fourier-transform mass spectra |
US4956788A (en) | 1988-11-28 | 1990-09-11 | University Of The Pacific | PC-based FT/ICR system |
US5233190A (en) | 1990-03-16 | 1993-08-03 | Leybold Inficon Inc. | Fourier transform molecular spectrometer |
US6017693A (en) | 1994-03-14 | 2000-01-25 | University Of Washington | Identification of nucleotides, amino acids, or carbohydrates by mass spectrometry |
US5668373A (en) | 1996-04-26 | 1997-09-16 | Trustees Of Tufts College | Methods and apparatus for analysis of complex mixtures |
GB9617852D0 (en) | 1996-08-27 | 1996-10-09 | Univ Manchester Metropolitan | Micro-organism identification |
GB9624927D0 (en) | 1996-11-29 | 1997-01-15 | Oxford Glycosciences Uk Ltd | Gels and their use |
US6428956B1 (en) | 1998-03-02 | 2002-08-06 | Isis Pharmaceuticals, Inc. | Mass spectrometric methods for biomolecular screening |
CA2339817A1 (en) | 1998-08-12 | 2000-02-24 | Zycos Inc. | Profiling and cataloging expressed protein tags |
US20020009394A1 (en) | 1999-04-02 | 2002-01-24 | Hubert Koster | Automated process line |
DE60031030T2 (en) | 1999-04-06 | 2007-05-10 | Micromass UK Ltd., Simonsway | Method for the identification of peptides and proteins by mass spectrometry |
EP1047107B1 (en) | 1999-04-06 | 2006-10-04 | Micromass UK Limited | Method of identifying peptides and protein by mass spectrometry |
US6677114B1 (en) | 1999-04-20 | 2004-01-13 | Target Discovery, Inc. | Polypeptide fingerprinting methods and bioinformatics database system |
JP4723725B2 (en) | 1999-04-20 | 2011-07-13 | ターゲット ディスカバリー, インコーポレイテッド | Methods for analyzing metabolic pathways |
US6446010B1 (en) | 1999-06-15 | 2002-09-03 | The Rockefeller University | Method for assessing significance of protein identification |
CA2298181C (en) | 2000-02-02 | 2006-09-19 | Dayan Burke Goodnough | Non-targeted complex sample analysis |
US20040038417A1 (en) | 2000-02-07 | 2004-02-26 | Cahill Dolores J. | Method for identifying and/or characterizing a (poly)peptide |
US7329489B2 (en) | 2000-04-14 | 2008-02-12 | Matabolon, Inc. | Methods for drug discovery, disease treatment, and diagnosis using metabolomics |
JP2003530130A (en) | 2000-04-14 | 2003-10-14 | メタボロン インコーポレイテッド | Methods for drug discovery, disease treatment and diagnosis using metabolomics |
WO2001092872A2 (en) | 2000-05-31 | 2001-12-06 | The Johns Hopkins University | Methods for using mass spectrometry to identify and classify filamentous fungi, yeasts, molds and pollen |
SE517259C2 (en) | 2000-06-14 | 2002-05-14 | Jan Eriksson | Molecular identification system |
US6680203B2 (en) * | 2000-07-10 | 2004-01-20 | Esperion Therapeutics, Inc. | Fourier transform mass spectrometry of complex biological samples |
DE10100238A1 (en) | 2001-01-05 | 2002-08-22 | Hannover Med Hochschule | Methods for predicting the potential risk for carcinoma and inflammatory bowel diseases and related tests |
EP1417629B1 (en) | 2001-07-06 | 2008-02-20 | Lipomics Technologies, Inc. | Generating, viewing, interpreting, and utilizing a quantitative database of metabolites |
BR0211697A (en) * | 2001-08-03 | 2004-07-13 | Biotron Ltd | Cancer marker and its uses in cancer diagnosis |
EP1425695A2 (en) | 2001-08-13 | 2004-06-09 | Beyong Genomics, Inc. | Method and system for profiling biological systems |
US20030108876A1 (en) | 2001-12-11 | 2003-06-12 | Speir Johnny Paul | Method for the application of FTMS to drug testing |
US7109038B2 (en) | 2002-06-13 | 2006-09-19 | The Johns Hopkins University | Occult blood detection in biological samples by laser desorption and matrix-assisted laser desorption/ionization mass spectrometry for biomedical applications |
WO2004090550A2 (en) * | 2003-04-08 | 2004-10-21 | Colotech A/S | A method for detection of colorectal cancer in human samples |
WO2004102190A1 (en) * | 2003-05-15 | 2004-11-25 | Europroteome Ag | Differential diagnosis of colorectal cancer and other diseases of the colon |
EP1794322A4 (en) | 2004-07-30 | 2009-10-28 | Sinai School Medicine | Klf6 alternative splice forms and a germline klf6 dna polymorphism associated with increased cancer risk |
-
2006
- 2006-09-12 SG SG2012041315A patent/SG182169A1/en unknown
- 2006-09-12 CA CA2619732A patent/CA2619732C/en active Active
- 2006-09-12 JP JP2008529437A patent/JP5038311B2/en active Active
- 2006-09-12 EP EP06817639A patent/EP1931995A4/en not_active Ceased
- 2006-09-12 KR KR1020087008798A patent/KR20080049821A/en not_active Application Discontinuation
- 2006-09-12 WO PCT/CA2006/001502 patent/WO2007030928A2/en active Application Filing
- 2006-09-12 SG SG201006597-7A patent/SG165370A1/en unknown
- 2006-09-12 CA CA2881326A patent/CA2881326A1/en not_active Abandoned
- 2006-09-12 AU AU2006291988A patent/AU2006291988B2/en active Active
- 2006-09-12 CA CA2772688A patent/CA2772688A1/en not_active Abandoned
- 2006-09-12 EP EP16187670.1A patent/EP3165925B1/en active Active
-
2016
- 2016-06-24 US US15/192,522 patent/US10697969B2/en active Active
-
2020
- 2020-05-20 US US16/879,155 patent/US20210041444A1/en active Pending
Non-Patent Citations (1)
Title |
---|
See references of EP1931995A4 * |
Cited By (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2644588A2 (en) | 2006-05-26 | 2013-10-02 | Phenomenome Discoveries Inc. | Biomarkers for diagnosing multiple sclerosis, and methods thereof |
EP3231789A1 (en) | 2006-05-26 | 2017-10-18 | Phenomenome Discoveries Inc. | Biomarkers for diagnosing multiple sclerosis, and methods thereof |
US9599618B2 (en) | 2006-12-21 | 2017-03-21 | Ajinomoto Co., Inc. | Method, apparatus, system, program, and computer-readable recording medium for evaluating colorectal cancer |
EP2682746A2 (en) | 2007-02-01 | 2014-01-08 | Phenomenome Discoveries Inc. | Methods for the diagnosis of ovarian cancer health states and risk of ovarian cancer health states |
EP2682746A3 (en) * | 2007-02-01 | 2014-04-23 | Phenomenome Discoveries Inc. | Methods for the diagnosis of ovarian cancer health states and risk of ovarian cancer health states |
AU2008210207B2 (en) * | 2007-02-01 | 2014-05-15 | Med-Life Discoveries Lp | Methods for the diagnosis of ovarian cancer health states and risk of ovarian cancer health states |
US9517222B2 (en) | 2007-02-08 | 2016-12-13 | Phenomenome Discoveries Inc. | Method for the treatment of senile dementia of the Alzheimer's type |
US10123989B2 (en) | 2007-02-08 | 2018-11-13 | Med-Life Discoveries Lp | Method of lowering cholesterol |
US8993623B2 (en) | 2007-02-08 | 2015-03-31 | Phenomenome Discoveries Inc. | Method for lowering cholesterol |
US9034923B2 (en) | 2007-02-08 | 2015-05-19 | Phenomenome Discoveries Inc. | Methods for the treatment of senile dementia of the alzheimer's type |
US8710429B2 (en) * | 2007-12-21 | 2014-04-29 | The Board Of Regents Of The University Of Ok | Identification of biomarkers in biological samples and methods of using same |
US20090159793A1 (en) * | 2007-12-21 | 2009-06-25 | Hanas Jay S | Identification of biomarkers in biological samples and methods of using same |
EP2279417A4 (en) * | 2008-05-28 | 2011-10-05 | Georgia Tech Res Inst | Metabolic biomarkers for ovarian cancer and methods of use thereof |
EP2279417A1 (en) * | 2008-05-28 | 2011-02-02 | Georgia Tech Research Corporation | Metabolic biomarkers for ovarian cancer and methods of use thereof |
US11079385B2 (en) | 2009-10-01 | 2021-08-03 | Med-Life Discoveries Lp | Serum-based biomarkers of pancreatic cancer and uses thereof for disease detection and diagnosis |
US10024857B2 (en) | 2009-10-01 | 2018-07-17 | Med-Life Discoveries Lp | Serum-based biomarkers of pancreatic cancer and uses thereof for disease detection and diagnosis |
US10656155B2 (en) | 2009-10-01 | 2020-05-19 | Med-Life Discoveries Lp | Serum-based biomarkers of pancreatic cancer and uses thereof for disease detection and diagnosis |
US10867706B2 (en) | 2010-07-20 | 2020-12-15 | Applied Invention, Llc | Multi-scale complex systems transdisciplinary analysis of response to therapy |
WO2013038371A1 (en) * | 2011-09-14 | 2013-03-21 | Basf Se | Means and methods for assessing gonadal toxicity |
EP2756297A4 (en) * | 2011-09-14 | 2015-10-14 | Basf Se | Means and methods for assessing gonadal toxicity |
US9689874B2 (en) | 2015-04-10 | 2017-06-27 | Applied Proteomics, Inc. | Protein biomarker panels for detecting colorectal cancer and advanced adenoma |
US10823744B2 (en) | 2016-05-30 | 2020-11-03 | Universal Diagnostics, S.L. | Methods and systems for metabolite and/or lipid-based detection of colorectal cancer and/or adenomatous polyps |
US10006925B2 (en) | 2016-05-30 | 2018-06-26 | Universal Diagnostics, S. L. | Methods and systems for metabolite and/or lipid-based detection of colorectal cancer and/or adenomatous polyps |
US11073522B2 (en) | 2016-10-03 | 2021-07-27 | Lincoln Memorial University | Structural validation of very long chain dicarboxylic acids |
WO2018067434A1 (en) * | 2016-10-03 | 2018-04-12 | Lincoln Memorial University | Identification and use of very long chain dicarboxylic acids for disease diagnosis, chemoprevention, and treatment |
CN110741007A (en) * | 2017-06-15 | 2020-01-31 | 医学生命探索有限公司 | Dicarboxylic acid fatty acid dimers and derivatives thereof as quantitative level standards in biological samples |
WO2018227306A1 (en) * | 2017-06-15 | 2018-12-20 | Med-Life Discoveries Lp | Dicarboxylic fatty acid dimers, and derivatives thereof, as standards for quantifying levels in biospecimens |
AU2018286510B2 (en) * | 2017-06-15 | 2022-09-15 | Med-Life Discoveries Lp | Dicarboxylic fatty acid dimers, and derivatives thereof, as standards for quantifying levels in biospecimens |
Also Published As
Publication number | Publication date |
---|---|
CA2772688A1 (en) | 2007-03-22 |
AU2006291988B2 (en) | 2013-02-28 |
EP3165925B1 (en) | 2021-09-08 |
KR20080049821A (en) | 2008-06-04 |
US20210041444A1 (en) | 2021-02-11 |
JP5038311B2 (en) | 2012-10-03 |
EP1931995A2 (en) | 2008-06-18 |
JP2009508091A (en) | 2009-02-26 |
US20160377622A1 (en) | 2016-12-29 |
WO2007030928A3 (en) | 2007-05-03 |
CA2881326A1 (en) | 2007-03-22 |
AU2006291988A1 (en) | 2007-03-22 |
CA2619732C (en) | 2012-06-12 |
EP3165925A1 (en) | 2017-05-10 |
EP1931995A4 (en) | 2010-08-04 |
US10697969B2 (en) | 2020-06-30 |
WO2007030928A8 (en) | 2007-06-14 |
CA2619732A1 (en) | 2007-03-22 |
SG165370A1 (en) | 2010-10-28 |
SG182169A1 (en) | 2012-07-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20210041444A1 (en) | Methods for diagnosing a colorectal cancer (crc) health state or change in crc health state, or for diagnosing risk of developing crc or the presence of crc in a subject | |
US20080255764A1 (en) | Methods for the Diagnosis of Colorectal Cancer and Ovarian Cancer by the Measurement of Vitamin E-Related Metabolites | |
AU2008210207B2 (en) | Methods for the diagnosis of ovarian cancer health states and risk of ovarian cancer health states | |
CA2644330C (en) | Biomarkers useful for diagnosing prostate cancer, and methods thereof | |
EP2483697B2 (en) | Method to diagnose pancreatic cancer | |
WO2016207391A1 (en) | Means and methods for diagnosing pancreatic cancer in a subject based on a biomarker panel | |
JP2013500275A (en) | Hydroxy fatty acid compounds and their use for disease treatment and diagnosis | |
Yu et al. | Simultaneous determination of phytoestrogens and key metabolites in breast cancer patients’ urine by liquid chromatography–tandem mass spectrometry | |
AU2013201305A1 (en) | Method for the diagnosis of colorectal cancer and ovarian cancer by the measurement of vitamin E-related metabolites |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 566252 Country of ref document: NZ Ref document number: 2619732 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2008529437 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 12008500638 Country of ref document: PH Ref document number: 200680033461.2 Country of ref document: CN |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 11910942 Country of ref document: US Ref document number: 2006291988 Country of ref document: AU |
|
REEP | Request for entry into the european phase |
Ref document number: 2006817639 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2006817639 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1287/KOLNP/2008 Country of ref document: IN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020087008798 Country of ref document: KR |
|
ENP | Entry into the national phase |
Ref document number: 2006291988 Country of ref document: AU Date of ref document: 20060912 Kind code of ref document: A |
|
WWP | Wipo information: published in national office |
Ref document number: 2006291988 Country of ref document: AU |
|
WWP | Wipo information: published in national office |
Ref document number: 2006817639 Country of ref document: EP |
|
ENPW | Started to enter national phase and was withdrawn or failed for other reasons |
Ref document number: PI0615913 Country of ref document: BR Kind code of ref document: A2 Free format text: PEDIDO CONSIDERADO RETIRADO EM RELACAO AO BRASIL E ARQUIVADO POR NAO ATENDER O DISPOSTO NOS ITENS 9 E 9.2.1 DO ATO NORMATIVO NO128/1997 DE 05/03/1997. |